Biogen (BIIB) financials
Biogen revenue and earnings by year
Biogen's revenue was $9.89 billion in the fiscal year to December 31, 2025, up 2.2% from the year before. Net income was $1.29 billion, 13.1% of revenue. Since the fiscal year to December 31, 2016, revenue has shrunk 1.6% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.9 | 9.7 | 9.8 | 10.2 | 11.0 | 13.4 | 14.4 | 13.5 | 12.3 | 11.4 |
| Revenue growth | 2.2% | -1.6% | -3.3% | -7.4% | -18.3% | -6.5% | 6.9% | 9.6% | 7.2% | — |
| Gross profit | 7.5 | 7.4 | 7.3 | 7.9 | 8.9 | 11.6 | 12.4 | 11.6 | 10.6 | 10.0 |
| Gross margin | 75.7% | 76.1% | 74.2% | 77.6% | 80.8% | 86.6% | 86.4% | 86.5% | 86.7% | 87.1% |
| Operating income | 1.6 | 1.9 | 1.3 | 3.6 | 1.7 | 5.0 | 7.0 | 5.9 | 5.3 | 5.2 |
| Operating margin | 15.7% | 19.7% | 13.2% | 35.3% | 15.9% | 37.5% | 49.0% | 43.8% | 43.6% | 45.0% |
| Net income | 1.3 | 1.6 | 1.2 | 3.0 | 1.6 | 4.0 | 5.9 | 4.4 | 2.5 | 3.7 |
| Net margin | 13.1% | 16.9% | 11.8% | 29.9% | 14.2% | 29.8% | 41.0% | 32.9% | 20.7% | 32.3% |
| Diluted EPS | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 | $24.45 | $31.47 | $21.60 | $11.92 | $16.92 |
| Free cash flow | 2.0 | 2.6 | 1.2 | 1.0 | 3.4 | 3.8 | 6.4 | 5.4 | 2.7 | 3.9 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open BIIB in Markets.
See also: BIIB valuation and P/E history · BIIB returns
No forecast, no recommendation. This page describes Biogen from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.